Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Alar Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
ROCO:6785'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.09 Med: -0.03 Max: 0.02
Current: -0.04
During the past 9 years, the highest Debt-to-EBITDA Ratio of Alar Pharmaceuticals was 0.02. The lowest was -0.09. And the median was -0.03.
ROCO:6785's Debt-to-EBITDA is ranked worse than 100% of 682
companies
in the Drug Manufacturers industry
Industry Median: 1.635
vs ROCO:6785: -0.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Alar Pharmaceuticals Debt-to-EBITDA Related Terms
Alar Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Alar Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alar Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alar Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alar Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alar Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Alar Pharmaceuticals (ROCO:6785) has a Debt-to-EBITDA of 0.03 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alar Pharmaceuticals. According to the industry distribution chart, Alar Pharmaceuticals ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Alar Pharmaceuticals' Debt-to-EBITDA too high?
Alar Pharmaceuticals' current Debt-to-EBITDA is 0.03. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Alar Pharmaceuticals' value of 0.03 is 98.2% below this industry median. Based on the distribution chart, Alar Pharmaceuticals ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alar Pharmaceuticals has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alar Pharmaceuticals' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alar Pharmaceuticals ranks #999999 out of 682 companies for Debt-to-EBITDA. This places Alar Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Alar Pharmaceuticals' value of 0.03 is 98.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alar Pharmaceuticals's current Debt-to-EBITDA of 0.03 is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alar Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alar Pharmaceuticals's current Debt-to-EBITDA is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alar Pharmaceuticals (ROCO:6785) is currently considered Fairly Valued. The stock's GF Value™ is NT$91.85, compared to a current price of NT$99.30 — trading 8.1% above its estimated fair value. The current Debt-to-EBITDA is 0.03 and 98.2% below the Drug Manufacturers industry median of 1.64. Alar Pharmaceuticals' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Alar Pharmaceuticals (ROCO:6785), the current Debt-to-EBITDA is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?
Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$99.30 is trading 8.1% above its estimated GF Value™ of NT$91.85.
GuruFocus considers Alar Pharmaceuticals to be Fairly Valued.
Key valuation signals for ROCO:6785:
Debt-to-EBITDA: 0.03
GF Value™: NT$91.85 vs. price of NT$99.30 (8.1% above fair value)
Industry Position: 98.2% below the Drug Manufacturers median (#999999 of 682)
No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
56GF Score
Get the complete analysis for ROCO:6785
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6785 has been successfully added to your 
